Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone plus Tirelizumab in recurrent/metastatic head and neck squamous cell carcinoma (Phase II)
ChiCTR2400083699Phase 2Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: objective remission rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
utidelonetislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400083699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083699.